Cargando…

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

SIMPLE SUMMARY: Immune checkpoint inhibitor therapy has been rapidly developed for the treatment of unresectable hepatocellular carcinoma (HCC). In the IMbrave150 trial, atezolizumab plus bevacizumab was seen as the first-line systemic drug therapy for unresectable HCC because overall survival and p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yano, Shigeki, Kawaoka, Tomokazu, Yamasaki, Shintaro, Johira, Yusuke, Kosaka, Masanari, Shirane, Yuki, Miura, Ryoichi, Amioka, Kei, Naruto, Kensuke, Yamaoka, Kenji, Fujii, Yasutoshi, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Miki, Daiki, Tsuge, Masataka, Teraoka, Yuji, Kouno, Hirotaka, Takaki, Shintaro, Mori, Nami, Tsuji, Keiji, Oka, Shiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670624/ https://www.ncbi.nlm.nih.gov/pubmed/38001666 http://dx.doi.org/10.3390/cancers15225406

Ejemplares similares

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma
por: Kosaka, Yumi, et al.
Publicado: (2022)

Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein
por: Kinami, Takahiro, et al.
Publicado: (2023)

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Ando, Yuwa, et al.
Publicado: (2022)

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
por: Ando, Yuwa, et al.
Publicado: (2021)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment
por: Yamaoka, Kenji, et al.
Publicado: (2022)

Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study
por: Johira, Yusuke, et al.
Publicado: (2023)

Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene
por: Miura, Ryoichi, et al.
Publicado: (2022)

Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices
por: Shirane, Yuki, et al.
Publicado: (2022)

Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma—Consideration of the Locations of Target Lesions
por: Yano, Shigeki, et al.
Publicado: (2023)

Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib
por: Fujii, Yasutoshi, et al.
Publicado: (2021)

Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma
por: Yamauchi, Masami, et al.
Publicado: (2023)

Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment
por: Tamura, Yosuke, et al.
Publicado: (2023)

Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
por: Yamauchi, Masami, et al.
Publicado: (2020)

Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy
por: Ohya, Kazuki, et al.
Publicado: (2019)

A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system
por: Yoshikawa, Yuki, et al.
Publicado: (2021)

Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib
por: Ono, Atsushi, et al.
Publicado: (2020)

Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib
por: Yamaoka, Kenji, et al.
Publicado: (2021)

Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study
por: Nagaoki, Yuko, et al.
Publicado: (2021)

Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis
por: Hiramatsu, Akira, et al.
Publicado: (2019)

Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures
por: Nishida, Yuno, et al.
Publicado: (2020)

Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study
por: Naruto, Kensuke, et al.
Publicado: (2022)

Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis
por: Fujino, Hatsue, et al.
Publicado: (2019)

In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism
por: Liu, Songyao, et al.
Publicado: (2021)

Early experience of seven hepatocellular carcinoma cases treated with regorafenib
por: Uchikawa, Shinsuke, et al.
Publicado: (2018)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients
por: Toshida, Katsuya, et al.
Publicado: (2022)

Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series
por: Ichimura, Takenori, et al.
Publicado: (2023)

Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection
por: Ohya, Kazuki, et al.
Publicado: (2019)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

A Case of Unresectable Combined Hepatocellular-Cholangiocarcinoma Successfully Treated with Lenvatinib
por: Osuga, Takahiro, et al.
Publicado: (2022)

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy
por: Nagaoki, Yuko, et al.
Publicado: (2017)

Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection
por: Ueda, Naoyuki, et al.
Publicado: (2020)

Efficacy and safety of lenvatinib–transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study
por: Oshita, Ko, et al.
Publicado: (2023)

Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells
por: Nakahara, Mai, et al.
Publicado: (2022)

Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients
por: Murakami, Eisuke, et al.
Publicado: (2021)

Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy
por: Ohya, Yuki, et al.
Publicado: (2020)

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
por: Su, Chung‐Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5jqbri1gdspj12i7dqk6086a6s